Prognostic factors in primary central nervous system lymphomas

Hematology/Oncology Clinics of North America

Volumn 19, Issue 4, 2005, Pages 629-649

  Ferreri, Andrés J M ^a   Reni, Michele ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); ANTHRACYCLINE; CYTARABINE; DNA METHYLTRANSFERASE; IDARUBICIN; METHOTREXATE; THIOTEPA;

AGE DISTRIBUTION; AREA UNDER THE CURVE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RISK; CANCER SURVIVAL; CELL INFILTRATION; CENTRAL NERVOUS SYSTEM TUMOR; CEREBROSPINAL FLUID ANALYSIS; CPG ISLAND; CREATININE CLEARANCE; DNA MICROARRAY; DNA REPAIR; DRUG MEGADOSE; GENE EXPRESSION; GENETIC POLYMORPHISM; HISTOPATHOLOGY; HUMAN; IMMUNOREACTIVITY; LUMBAR PUNCTURE; LYMPHOMA; PATHOGENESIS; PHARMACOGENETICS; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROMOTER REGION; REVIEW; SCORING SYSTEM; T LYMPHOCYTE; TREATMENT FAILURE;

AGE DISTRIBUTION; CENTRAL NERVOUS SYSTEM NEOPLASMS; HUMANS; LYMPHOMA; PROGNOSIS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 23244454789     PISSN: 08898588     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hoc.2005.05.005     Document Type: Review

References (79)

1. N. Hayabuchi, Y. Shibamoto, and Y. Onizuka Primary central nervous system lymphoma in Japan: a nationwide survey Int J Radiat Oncol Biol Phys 44 2 1999 265 272
2. J. Corry, J.G. Smith, and A. Wirth Primary central nervous system lymphoma: age and performance status are more important than treatment modality Int J Radiat Oncol Biol Phys 41 3 1998 615 620
3. L.E. Abrey, J. Yahalom, and L.M. Deangelis Treatment for primary CNS lymphoma: the next step J Clin Oncol 18 17 2000 3144 3150
4. A.J. Ferreri, J.Y. Blay, and M. Reni Prognostic scoring system for primary CNS lymphomas: the International Extranodal Lymphoma Study Group experience J Clin Oncol 21 2 2003 266 272
5. D.F. Braus, K. Schwechheimer, and H.K. Muller-Hermelink Primary cerebral malignant non-Hodgkin's lymphomas: a retrospective clinical study J Neurol 239 3 1992 117 124
6. J.M. Michalski, D.M. Garcia, and E. Kase Primary central nervous system lymphoma: analysis of prognostic variables and patterns of treatment failure Radiology 176 3 1990 855 860
7. I.F. Pollack, L.D. Lunsford, and J.C. Flickinger Prognostic factors in the diagnosis and treatment of primary central nervous system lymphoma Cancer 63 5 1989 939 947
8. D.F. Nelson Radiotherapy in the treatment of primary central nervous system lymphoma (PCNSL) J Neurooncol 43 3 1999 241 247
9. P. O'Brien, D. Roos, and G. Pratt Phase II multicenter study of brief single-agent methotrexate followed by irradiation in primary CNS lymphoma J Clin Oncol 18 3 2000 519 526
10. L.M. DeAngelis, W. Seiferheld, and S.C. Schold Combination chemotherapy and radiotherapy for primary central nervous system lymphoma: Radiation Therapy Oncology Group Study 93-10 J Clin Oncol 20 24 2002 4643 4648
11. H. Pels, I.G. Schmidt-Wolf, and A. Glasmacher Primary central nervous system lymphoma: results of a pilot and phase II study of systemic and intraventricular chemotherapy with deferred radiotherapy J Clin Oncol 21 24 2003 4489 4495
12. B.P. O'Neill, J.R. O'Fallon, and J.D. Earle Primary central nervous system non-Hodgkin's lymphoma: survival advantages with combined initial therapy? Int J Radiat Oncol Biol Phys 33 3 1995 663 673
13. L.E. Abrey, L.M. DeAngelis, and J. Yahalom Long-term survival in primary CNS lymphoma J Clin Oncol 16 3 1998 859 863
14. E.M. Bessell, A. Lopez-Guillermo, and S. Villa Importance of radiotherapy in the outcome of patients with primary CNS lymphoma: an analysis of the CHOD/BVAM regimen followed by two different radiotherapy treatments J Clin Oncol 20 1 2002 231 236
15. Y. Shibamoto, K. Sasai, and N. Oya Systemic chemotherapy with vincristine, cyclophosphamide, doxorubicin and prednisolone following radiotherapy for primary central nervous system lymphoma: a phase II study J Neurooncol 42 2 1999 161 167
16. C. Schultz, C. Scott, and W. Sherman Preirradiation chemotherapy with cyclophosphamide, doxorubicin, vincristine, and dexamethasone for primary CNS lymphomas: initial report of radiation therapy oncology group protocol 88-06 J Clin Oncol 14 2 1996 556 564
17. K.A. Jellinger, and W. Paulus Primary central nervous system lymphomas-an update J Cancer Res Clin Oncol 119 1 1992 7 27
18. M. Reni, A.J. Ferreri, and M.P. Garancini Therapeutic management of primary central nervous system lymphoma in immunocompetent patients: results of a critical review of the literature Ann Oncol 8 3 1997 227 234
19. T.L. Helle, R.H. Britt, and T.V. Colby Primary lymphoma of the central nervous system. Clinicopathological study of experience at Stanford J Neurosurg 60 1 1984 94 103
20. A.J. Ferreri, M. Reni, and E. Villa Therapeutic management of primary central nervous system lymphoma: lessons from prospective trials Ann Oncol 11 8 2000 927 937
21. A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project N Engl J Med 329 14 1993 987 994
22. J.Y. Blay, D. Bouhour, and C. Carrie The C5R protocol: a regimen of high-dose chemotherapy and radiotherapy in primary cerebral non-Hodgkin's lymphoma of patients with no known cause of immunosuppression Blood 86 8 1995 2922 2929
23. J.Y. Blay, T. Conroy, and C. Chevreau High-dose methotrexate for the treatment of primary cerebral lymphomas: analysis of survival and late neurologic toxicity in a retrospective series J Clin Oncol 16 3 1998 864 871
24. A.J. Ferreri, M. Reni, and F. Pasini A multicenter study of treatment of primary CNS lymphoma Neurology 58 10 2002 1513 1520
25. S.A. Levinson, and R.P. MacFate Clinical laboratory diagnosis 1961 Lea & Febiger Philadelphia
26. J.Y. Blay, C. Lasset, and C. Carrie Multivariate analysis of prognostic factors in patients with non HIV- related primary cerebral lymphoma. A proposal for a prognostic scoring Br J Cancer 67 5 1993 1136 1141
27. A.J. Ferreri, M. Bernardi, and S. Dell'Oro CLIMT-2: an ongoing phase-II multicentre trial of MATILde chemotherapy regimen (methotrexate-cytarabine- thiotepa-idarubicin) in HIV-negative primary CNS lymphomas (PCNSL) Proc Am Soc Clin Oncol 21 2002 2077a
28. International Extranodal Lymphoma Study Group IELSG #20 trial 2003 Available at: http://www.ielsg.org/trialsonfr.html Accessed November 11, 2004
29. S.L. Barrans, I. Carter, and R.G. Owen Germinal center phenotype and bcl-2 expression combined with the International Prognostic Index improves patient risk stratification in diffuse large B-cell lymphoma Blood 99 4 2002 1136 1143
30. E.M. Bessell, F. Graus, and A. Lopez-Guillermo Primary non-Hodgkin's lymphoma of the CNS treated with CHOD/BVAM or BVAM chemotherapy before radiotherapy: long-term survival and prognostic factors Int J Radiat Oncol Biol Phys 59 2 2004 501 508
31. A.J.M. Ferreri, and M. Reni Establishing a prognostic score for primary CNS lymphomas Int J Radiat Oncol Biol Phys 61 1 2005 303 304
32. T.N. Shenkier, J.Y. Blay, and B.P. O'Neill Primary CNS lymphoma of T-cell origin: a descriptive analysis from the international primary CNS lymphoma collaborative group J Clin Oncol 23 10 2005 2233 2239
33. N. Kambham, Y. Chang, and A.Y. Matsushima Primary low-grade B-cell lymphoma of mucosa-associated lymphoid tissue (MALT) arising in dura Clin Neuropathol 17 6 1998 311 317
34. A. Sanjeevi, J. Krishnan, and P.R. Bailey Extranodal marginal zone B-Cell lymphoma of malt type involving the cavernous sinus Leuk Lymphoma 42 5 2001 1133 1137
35. E. Braks, H. Urbach, and H. Pels Primary central nervous system immunocytoma: MRI and spectroscopy Neuroradiology 42 10 2000 738 741
36. A.J.M. Ferreri, R. Stefano, and P.A. Scalfaro Primary central nervous system lymphomas: clinico-pathological characteristics and therapeutic management of rare entities Haematologica 89 1 2004 209 215
37. D.H. George, B.W. Scheithauer, and F.V. Aker Primary anaplastic large cell lymphoma of the central nervous system: prognostic effect of ALK-1 expression Am J Surg Pathol 27 4 2003 487 493
38. M. Ponzoni, F. Berger, and C. Chassagne Reactive perivascular T-cell infiltrate is an independent favorable prognostic factor in primary central nervous system lymphomas (PCNSL) in immunocompetent patients Ann Oncol 13 Suppl 2 2002 264
39. A. Alizadeh, M.B. Eisen, and R.E. Davis Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling Nature 403 2000 503 511
40. I.S. Lossos, C.D. Jones, and R. Warnke Expression of a single gene, BCL-6, strongly predicts survival in patients with diffuse large B-cell lymphoma Blood 98 4 2001 945 951
41. K.L. Ferguson, R.A. Warnke, and I. Lossos Quantitative immunohistochemical analysis of bcl-6 protein expression in diffuse large B-cell lymphoma J Clin Pathol 55 Suppl 1 2002 49a
42. S. Camilleri-Broet, V. Delwail, and A. Moreau Primary central nervous system lymphomas (PCNSL) are distinct from systemic DLBCL for expression pattern of germinal center and activation B-cell markers. A GOELAMS study Blood 104 11 2004 623a 624a
43. K.M. Braaten, R.A. Betensky, and L. de Leval BCL-6 expression predicts improved survival in patients with primary central nervous system lymphoma Clin Cancer Res 9 3 2003 1063 1069
44. C.C. Chang, B. Kampalath, and C. Schultz Expression of p53, c-Myc, or Bcl-6 suggests a poor prognosis in primary central nervous system diffuse large B-cell lymphoma among immunocompetent individuals Arch Pathol Lab Med 127 2 2003 208 212
45. R. Yamanaka, S. Akutagawa, and F. Taguchi Selection of surrogate marker genes in primary central nervous system lymphomas for radio-chemotherapy by DNA array analysis of gene expression profiles Int J Oncol 23 4 2003 913 923
46. R. Boonstra, A. Koning, and M. Mastik Analysis of chromosomal copy number changes and oncoprotein expression in primary central nervous system lymphomas: frequent loss of chromosome arm 6q Virchows Arch 443 2 2003 164 169
47. M. Nakamura, M. Kishi, and T. Sakaki Novel tumor suppressor loci on 6q22-23 in primary central nervous system lymphomas Cancer Res 63 4 2003 737 741
48. S.B. Baylin, J.G. Herman, and J.R. Graff Alterations in DNA methylation: a fundamental aspect of neoplasia Adv Cancer Res 72 1998 141 196
49. R. Gorlick, E. Goker, and T. Trippett Intrinsic and acquired resistance to methotrexate in acute leukemia N Engl J Med 335 14 1996 1041 1048
50. F.M. Sirotnak, and B. Tolner Carrier-mediated membrane transport of folates in mammalian cells Annu Rev Nutr 19 1999 91 122
51. T. Trippett, S. Schlemmer, and Y. Elisseyeff Defective transport as a mechanism of acquired resistance to methotrexate in patients with acute lymphocytic leukemia Blood 80 5 1992 1158 1162
52. R. Gorlick, E. Goker, and T. Trippett Defective transport is a common mechanism of acquired methotrexate resistance in acute lymphocytic leukemia and is associated with decreased reduced folate carrier expression Blood 89 3 1997 1013 1018
53. W. Guo, J.H. Healey, and P.A. Meyers Mechanisms of methotrexate resistance in osteosarcoma Clin Cancer Res 5 3 1999 621 627
54. J. Worm, A.F. Kirkin, and K.N. Dzhandzhugazyan Methylation-dependent silencing of the reduced folate carrier gene in inherently methotrexate- resistant human breast cancer cells J Biol Chem 276 43 2001 39990 40000
55. A.J. Ferreri, S. Dell'Oro, and D. Capello Aberrant methylation in the promoter region of the reduced folate carrier gene is a potential mechanism of resistance to methotrexate in primary central nervous system lymphomas Br J Haematol 126 2004 657 664
56. A.S. Levy, H.N. Sather, and P.G. Steinherz Reduced folate carrier and dihydrofolate reductase expression in acute lymphocytic leukemia may predict outcome: a Children's Cancer Group Study J Pediatr Hematol Oncol 25 9 2003 688 695
57. M. Esteller, G. Gaidano, and S.N. Goodman Hypermethylation of the DNA repair gene O(6)-methylguanine DNA methyltransferase and survival of patients with diffuse large B-cell lymphoma J Natl Cancer Inst 94 1 2002 26 32
58. A.E. Pegg, M.E. Dolan, and R.C. Moschel Structure, function, and inhibition of O6-alkylguanine-DNA alkyltransferase Prog Nucleic Acid Res Mol Biol 51 1995 167 223
59. P. Gonzalez-Gomez, M.J. Bello, and D. Arjona CpG island methylation of tumor-related genes in three primary central nervous system lymphomas in immunocompetent patients Cancer Genet Cytogenet 142 1 2003 21 24
60. M. Reni, W. Mason, and F. Zaja Salvage chemotherapy with temozolomide in primary CNS lymphomas: preliminary results of a phase II trial Eur J Cancer 40 11 2004 1682 1688
61. W.E. Evans, W.R. Crom, and M. Abromowitch Clinical pharmacodynamics of high-dose methotrexate in acute lymphocytic leukemia. Identification of a relation between concentration and effect N Engl J Med 314 8 1986 471 477
62. G. Bacci, S. Ferrari, and N. Delepine Predictive factors of histologic response to primary chemotherapy in osteosarcoma of the extremity: study of 272 patients preoperatively treated with high-dose methotrexate, doxorubicin, and cisplatin J Clin Oncol 16 2 1998 658 663
63. N. Delepine, G. Delepine, and H. Cornille Dose escalation with pharmacokinetics monitoring in methotrexate chemotherapy of osteosarcoma Anticancer Res 15 2 1995 489 494
64. N. Graf, K. Winkler, and M. Betlemovic Methotrexate pharmacokinetics and prognosis in osteosarcoma J Clin Oncol 12 7 1994 1443 1451
65. A.J. Ferreri, E. Guerra, and M. Regazzi Area under the curve of methotrexate and creatinine clearance are outcome-determining factors in primary CNS lymphomas Br J Cancer 90 2 2004 353 358
66. D.W. Cockcroft, and M.H. Gault Prediction of creatinine clearance from serum creatinine Nephron 16 1 1976 31 41
67. W.M. Hryniuk, and M. Goodyear The calculation of received dose intensity J Clin Oncol 8 12 1990 1935 1937
68. S.W. Pitman, and E. Frei Weekly methotrexate-calcium leucovorin rescue: effect of alkalinization on nephrotoxicity; pharmacokinetics in the CNS; and use in CNS non- Hodgkin's lymphoma Cancer Treat Rep 61 4 1977 695 701
69. W.E. Evans, P.R. Hutson, and C.F. Stewart Methotrexate cerebrospinal fluid and serum concentrations after intermediate-dose methotrexate infusion Clin Pharmacol Ther 33 3 1983 301 307
70. P. Chiusolo, G. Reddiconto, and I. Casorelli Preponderance of methylenetetrahydrofolate reductase C677T homozygosity among leukemia patients intolerant to methotrexate Ann Oncol 13 12 2002 1915 1918
71. C.M. Ulrich, Y. Yasui, and R. Storb Pharmacogenetics of methotrexate: toxicity among marrow transplantation patients varies with the methylenetetrahydrofolate reductase C677T polymorphism Blood 98 1 2001 231 234
72. T. Strunk, S. Gottschalk, and W. Goepel Subacute leukencephalopathy after low-dose intrathecal methotrexate in an adolescent heterozygous for the MTHFR C677T polymorphism Med Pediatr Oncol 40 1 2003 48 50
73. G. Toffoli, A. Russo, and F. Innocenti Effect of methylenetetrahydrofolate reductase C677T polymorphism on toxicity and homocysteine plasma level after chronic methotrexate treatment of ovarian cancer patients Int J Cancer 103 3 2003 294 299
74. Y. Berkun, D. Levartovsky, and A. Rubinow Methotrexate related adverse effects in patients with rheumatoid arthritis are associated with the A1298C polymorphism of the MTHFR gene Ann Rheum Dis 63 10 2004 1227 1231
75. M. Reni, and A.J. Ferreri Is withdrawal of consolidation radiotherapy an evidence-based strategy in primary central nervous system lymphomas? J Clin Oncol 22 6 2004 1165 1167
76. S. Camilleri-Broet, A. Martin, and A. Moreau Primary central nervous system lymphomas in 72 immunocompetent patients, pathologic findings and clinical correlations Am J Clin Pathol 110 1998 607 612
77. S. Vezmar, A. Becker, and U. Bode Biochemical and clinical aspects of methotrexate neurotoxicity Chemotherapy 49 1-2 2003 92 104
78. C.T. Quinn, J.C. Griener, and T. Bottiglieri Elevation of homocysteine and excitatory amino acid neurotransmitters in the CSF of children who receive methotrexate for the treatment of cancer J Clin Oncol 15 8 1997 2800 2806
79. S. Kishi, J. Griener, and C. Cheng Homocysteine, pharmacogenetics, and neurotoxicity in children with leukemia J Clin Oncol 21 16 2003 3084 3091